Tadamitsu Kishimoto

Source: Wikipedia, the free encyclopedia.
Tadamitsu Kishimoto
King Faisal International Prize(2017)
Tang Prize
(2020)
Scientific career
FieldsBiology

Tadamitsu Kishimoto (岸本 忠三, Kishimoto Tadamitsu, born May 7, 1939 in

cytokines, most famously, interleukin 6
.

He did postdoctoral work under

IgE at Johns Hopkins University
.

He is listed by the Institute for Scientific Information (ISI) as a highly cited biologist and he is also in the top ten of h-index of living biologists.

Life

Tadamitsu Kishimoto, who was born in

Castleman's disease, rheumatoid arthritis and juvenile idiopathic arthritis
.

He has received numerous awards, including the

German Academy of Sciences Leopoldina in 2005.[1]
He served as a president of the International Immunopharmacology Society, International Cytokine Society and the Japanese Immunology Society. He is an honorary member in American Association of Immunologists and American Society of Hematology. In 2020, He received the prestigious Tang Prize in Biopharmaceutical Science.

IL-6

In the early 1970s, Kishimoto discovered the activity inducing antibody production in culture supernatants of T cells. Furthermore, he demonstrated that the activity for inducing IgG and IgE antibodies could be separated.[2] Later, this finding led to the discovery of the dichotomy of helper T cells, Th1 and Th2. On the basis of these early studies, Kishimoto discovered and cloned interleukin-6 and its receptor and delineated the signaling pathway used by IL-6 and the set of related cytokines that utilize gp-130, which he also discovered.

NF-IL-6 and STAT3, both central to the action of IL-6.[7] He further discovered a family of suppressors of cytokine signaling, the SOCS molecules, that are key regulators of cytokine function.[8]
He demonstrated the involvement of IL-6 in the pathogenesis of cardiac myxomas, multiple myeloma, Castleman’s disease, rheumatoid arthritis, Crohn's disease and juvenile idiopathic arthritis (JIA). He identified IL-6 as a hepatocyte stimulating factor which induces acute phase reactions. He prepared a monoclonal anti-IL-6 receptor antibody that was subsequently humanized and has been shown to be of great therapeutic value in a series of autoinflammatory diseases including Castleman's Disease, rheumatoid arthritis and juvenile idiopathic arthritis.[9] His work has dominated the field of proinflammatory cytokines and has established paradigms for the study of all of cytokine biology, ranging from discovery of the cytokine and its receptor, through signaling and transcriptional mechanisms, to the utilization of such knowledge to develop highly effective therapeutics.[10] A series of his IL-6 studies for 35 years since 1973 have been highly appreciated; He was ranked as the world’s 8th-most-cited researchers between 1983 and 2002 and he is in the top ten of h-index of living biologists.

Recognition

Kishimoto receives the Crafoord Prize

Awards

  • Behring-Kitasato Prize from Hoechst Japan, 1982
  • Osaka Science Prize, 1983
  • Erwin von Bälz Prize, 1986
  • Takeda Prize, 1988
  • Asahi Prize, 1988
  • Prize of The Japanese Medical Association, 1990
  • Scientific Achievement Award from the International Association of Allergology and Clinical Immunology, 1991
  • Imperial Prize of the Japan Academy, 1992
  • Sandoz Prize for Immunology
    from International Union of Immunology Society, 1992
  • The Avery-Landsteiner Prize from the German Immunology Society, 1996
  • The Donald Seldin Award from the International Society of Nephrology, 1999
  • ISI Citation Laureate Award
    , 2000
  • Robert Koch Prize
    - Robert Koch Gold Medal, 2003
  • Honorary Lifetime Achievement Awards, International Cytokine Society, 2006
  • 7th International Award of the Japan Rheumatism Foundation, 2008
  • The Crafoord Prize from the Royal Swedish Academy of Sciences, 2009
  • Japan Prize, 2011
  • King Faisal International Prize
    , 2017
  • Tang Prize in Biopharmaceutical Science, 2020
  • Clarivate Citation Laureates, 2021

Honors

  • Person of Cultural Merit, Japan 1990
  • Foreign Associate, The US National Academy of Sciences, 1991
  • Honorary Member, the American Association of Immunologists, 1992
  • Honorary Citizen, Tondabayashi City, 1992
  • Member, the Japan Academy, 1995
  • Foreign Associate member, the Institute of Medicine of the National Academy of Science, USA, 1997
  • Honorary member, the American Society of Hematology, 1997
  • The Order of Culture of Japan, 1998
  • Doctor Honoris Causa, Universidad Technologica de Santiago, UTESA, 2001
  • Honorary Member, International Association of Dental Research, 2001
  • Honorary Professor, the
    Fourth Military Medical University
    , Xi’an, China, 2002
  • Honorary Member, World Innovation Foundation, 2002
  • Doctor of Science, Honoris Causa, Mahidol University, 2003
  • Clemens von Pirquet Distinguished Professor, Medicine and Immunology, University California, Davis, 2004
  • Member,
    German Academy of Sciences Leopoldina
    , 2005

References

  1. ^ a b c d e f g h i j k http://www.japanprize.jp/en/prize_prof_2011_kishimoto.html, The Japan Prize Foundation
  2. ^ Kishimoto, T., and K. Ishizaka. Regulation of antibody response in vitro. VII. Enhancing soluble factors for IgG and IgE antibody response. J. Immunol. 111:1194-1205, 1973.
  3. ^ Hirano, T., K. Yasukawa, H. Harada, T. Taga, Y. Watanabe, T. Matsuda, S. Kashiwamura, K. Nakajima, K. Koyama, A. Iwamatsu, S. Tsunasawa, F. Sakiyama, H. Matsui, Y. Takahara, T. Taniguchi, and T. Kishimoto. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73-76, 1986.
  4. ^ Kawano, M., T. Hirano, T. Matsuda, T. Taga, Y. Horii, K. Iwato, H. Asaoku, B. Tang, O. Tanabe, H. Tanaka, A. Kuramoto, and T. Kishimoto. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83-85, 1988.
  5. ^ Yamasaki, K., T. Taga, Y. Hirata, H. Yawata, Y. Kawanishi, B. Seed, T. Taniguchi, T. Hirano, and T. Kishimoto. Cloning and expression of human interleukin 6 (BSF-2/IFNb2) receptor. Science 241:825-828, 1988.
  6. ^ Taga, T., M. Hibi, Y. Hirata, K. Yamasaki, K. Yasukawa, T. Matsuda, T. Hirano, and T. Kishimoto. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573-581, 1989.
  7. ^ Akira, S., Y.Nishio, M.Inoue, X.Wang, S.Wei, T.Matsusaka, K.Yoshida, T.Sudo, M.Naruto, and T.Kishimoto. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77: 63-71, 1994.
  8. ^ Naka, T., M. Narazaki, M.Hirata, T.Matsumoto, S.Minamoto, A.Aono, N.Nishimoto, T.Kajita, T.Taga, K.Yoshizaki, S.Akira, and T.Kishimoto. Structure and function of a new STAT-induced STAT inhibitor-1. Nature 387:924-929, 1997.
  9. ^ Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, T. Kishimoto. Efficary and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371(9617):998-1006, 2008
  10. ^ Kishimoto, T. Interleukin-6: From basic science to medicine, 40 years in immunology. Annu. Rev. Immunol. 23:1-21, 2005.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Tadamitsu_Kishimoto&oldid=1174960726"